Biopharmaceutical company Dermavant Sciences is giving refunds to health care providers that paid above the 340B ceiling price for Vtama, a non-steroidal cream to treat plaque psoriasis.
The U.S. Health Resources and Services Administration posted Dermavant’s notice to 340B covered entities last week. The company, a subsidiary of Roivant Sciences, began selling Vtama in May 2022. It said it discovered that some entities may have bought Vtama at wholesaler acquisition price rather than at the 340B ceiling price from Q2 2022 through Q1 2023.
Biopharmaceutical company Dermavant Sciences is giving refunds to health care providers that paid above the 340B ceiling price for Vtama, a non-steroidal cream to treat plaque psoriasis. The U.S. Health Resources and Services Administration posted Dermavant’s notice to 340B covered […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
